James Edgemond sold $2.7M of UTHR
CFO AND TREASURER at UNITED THERAPEUTICS Corp. 7,800 shares at an average of $350.00, traded Oct 28, 2024, filed Oct 29, 2024.
Score components
- +22RoleCFO
- +25Trade size$2.7M at market
- +20Share of holdings soldSold 76% of holdings
- +15Cluster6 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +7.2%, 3m +5.1%, 6m -14.8%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-025696, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 28, 2024 | MOption exercise Common Stock10b5-1 | +3,267 | $120.26 | $393k | 10,245 | Oct 29, 2024 |
| Oct 28, 2024 | SOpen-market sale Common Stock10b5-1 | -3,267 | $350.00 | $1.1M | 6,978 | Oct 29, 2024 |
| Oct 28, 2024 | MOption exercise Common Stock10b5-1 | +3,400 | $117.76 | $400k | 10,378 | Oct 29, 2024 |
| Oct 28, 2024 | SOpen-market sale Common Stock10b5-1 | -3,400 | $350.00 | $1.2M | 6,978 | Oct 29, 2024 |
| Oct 28, 2024 | MOption exercise Common Stock10b5-1 | +817 | $120.26 | $98k | 7,795 | Oct 29, 2024 |
| Oct 28, 2024 | SOpen-market sale Common Stock10b5-1 | -557 | $350.00 | $195k | 7,238 | Oct 29, 2024 |
| Oct 28, 2024 | MOption exercise Common Stock10b5-1 | +850 | $117.76 | $100k | 8,088 | Oct 29, 2024 |
| Oct 28, 2024 | SOpen-market sale Common Stock10b5-1 | -576 | $350.00 | $202k | 7,512 | Oct 29, 2024 |
| Oct 28, 2024 | MOption exercise Stock Optionsderivative10b5-1 | -3,267 | $0.00 | $0 | 4,901 | Oct 29, 2024 |
| Oct 28, 2024 | MOption exercise Stock Optionsderivative10b5-1 | -3,400 | $0.00 | $0 | 116,600 | Oct 29, 2024 |
| Oct 28, 2024 | MOption exercise Stock Optionsderivative10b5-1 | -817 | $0.00 | $0 | 4,084 | Oct 29, 2024 |
| Oct 28, 2024 | MOption exercise Stock Optionsderivative10b5-1 | -850 | $0.00 | $0 | 115,750 | Oct 29, 2024 |
Related signals
Other insiders at UNITED THERAPEUTICS Corp and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.2M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.1M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.2M 9,500 shares | -3% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $5.5M 9,500 shares | -3% | |
| 18Weak | UNITED THERAPEUTICS Corp | Paul A Mahon EVP & GENERAL COUNSEL | $4.7M 8,300 shares | -16% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $3.9M 7,580 shares | -2% | |
| 38Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $1.1M 1,920 shares | -1% | |
| 23Weak | UNITED THERAPEUTICS Corp | Martine A Rothblatt Chairperson & CEO | $4.5M 9,500 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.